Mira Dx, Inc.
New Haven, CT · Founded 2008 · CIK 0001471338 · Biotech · Private
Genetic biomarkers for predicting cancer treatment toxicity and efficacy
miradx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $2.1M
- 1 Form D · Sep 2009
- 205 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 11
- 3 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20092010
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,088,459 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2546 | Regenerate, Inc. | — | $2.3M |
| 2547 | ANAGIN | — | $2.3M |
| 2548 | Amplo Biotechnology, Inc. | — | $2.2M |
| 2549 | Mira Dx, Inc. | — | $2.1M |
| 2550 | CellVax Therapeutics, Inc. | — | $2.1M |
| 2551 | BACTRIA PHARMACEUTICALS LLC | — | — |
| 2552 | Regenimo Biosciences, Inc. | — | $2.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Barbara Mignogna-KorusDirector · Executive Officer
- Stephen MillerDirector · Executive Officer
- Mary PolanDirector
- Andrew WeidhaasDirector · Executive Officer
Patents
- Biomarkers For Predicting Tumor Response To And Toxicity Of Immunotherapyapplication
- Biomarkers For Predicting Tumor Response To And Toxicity Of Immunotherapygranted
- Biomarkers For Predicting Toxicity Of Radiationapplication
- Biomarkers For Predicting Tumor Response To And Toxicity Of Immunotherapygranted
- Methods For Treating Or Preventing Cancer In A Kras-variant Patient And For Diagnosing Risk Of Developing Multiple Primary Breast Tumorsapplication
- Immune-based Treatment Of Kras-variant Cancer Patientsapplication
- Methods For Treating Or Preventing Cancer In A Kras-variant Patient And For Diagnosing Risk Of Developing Multiple Primary Breast Tumorsgranted
- Immune-based Treatment Of Kras-variant Cancer Patientsapplication
- Biomarkers For Predicting Toxicity Of Radiationapplication
- Biomarkers For Predicting Toxicity Of Radiationapplication
- Biomarkers For Predicting Tumor Response To And Toxicity Of Immunotherapyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.